II. Indications
- Fibromyalgia (FDA approved)
- Major Depression (off label; other SNRI is preferred)
III. Safety
- Unknown safety in Lactation
- Pregnancy Category C
IV. Preparations
- Milnacipran (Savella) 12.5 mg, 25 mg, 50 mg, 100 mg tablets
V. Dosing: Fibromyalgia
- Start: 12.5 mg orally daily for 2-3 days, then
- Next: 12.5 mg orally twice daily for 2-3 days, then
- Next: 25 mg orally twice daily
- Next: May increase to 50 mg orally twice daily
- Maximum: 200 mg/day
- Decrease dose by 50% in severe renal Impairment (eGFR <30 ml/min)
VI. Adverse Effects
VII. Drug Interactions
- Avoid with Monoamine Oxidase Inhibitors (MAO Inhibitors), including Linezolid and methylene blue
VIII. Resources
IX. References
- Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 38-9
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
Images: Related links to external sites (from Bing)
Related Studies
| savella (on 1/14/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| SAVELLA 100 MG TABLET | $7.07 each | |
| SAVELLA 12.5 MG TABLET | $7.01 each | |
| SAVELLA 25 MG TABLET | $7.08 each | |
| SAVELLA 50 MG TABLET | $7.07 each | |
| SAVELLA TITRATION PACK | $7.04 each | |